My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Asian Paints moves higher after consolidating investments in overseas subsidiaries
Sep 20,2016

The announcement was made after market hours yesterday, 19 September 2016.

Meanwhile, the S&P BSE Sensex was down 123.87 points or 0.43% at 28,510.63

On BSE, so far 22,000 shares were traded in the counter as against average daily volume of 94,372 shares in the past one quarter. The stock hit a high of Rs 1,173 and a low of Rs 1,164 so far during the day. The stock hit a record high of Rs 1,212.95 on 6 September 2016. The stock had hit a 52-week low of Rs 785 on 9 November 2015. The stock had outperformed the market over the past 30 days till 19 September 2016, rising 4.32% compared with Sensexs 1.99% rise. The scrip also outperformed the market in past one quarter, gaining 18.6% as against Sensexs 6.79% rise.

The large-cap company has equity capital of Rs 95.92 crore. Face value per share is Re 1.

Asian Paints said that as a part of the companys plan to consolidate its investments in the overseas subsidiaries, Asian Paints (International) (APIL), Mauritius, a wholly owned subsidiary of the company, has transferred its entire holding of 99.18% held in the subsidiary company, Asian Paints (Lanka), Sri Lanka, to Berger International, Singapore, a wholly owned subsidiary of APIL. The transfer process has been completed on 19 September 2016.

Asian Paints consolidated net profit rose 18.47% to Rs 552.56 crore on 9.25% rise in total income to Rs 3709.31 crore in Q1 June 2016 over Q1 June 2015.

Asian Paints is Indias leading paint company and ranked among the top ten decorative coatings companies in the world. The company along with its subsidiaries have operations in 19 countries across the world and 26 paint manufacturing facilities, servicing consumers in over 65 countries.

Powered by Capital Market - Live News

Jubilant FoodWorks drops after resignation of its CEO
Sep 20,2016

The announcement was made after market hours yesterday, 19 September 2016.

Meanwhile, the S&P BSE Sensex was down 151.92 points or 0.53% at 28,482.58.

On BSE, so far 3.58 lakh shares were traded in the counter as against average daily volume of 44,498 shares in the past one quarter. The stock hit a high of Rs 950 and a low of Rs 923.50 so far during the day. The stock had hit a 52-week low of Rs 896.65 on 12 February 2016. The stock had hit a 52-week high of Rs 1,689.30 on 6 October 2015. The stock had underperformed the market over the past one month till 19 September 2016, falling 18.03% compared with Sensexs 1.99% rise. The scrip had also underperformed the market in past one quarter, sliding 6.71% as against Sensexs 7.54% rise.

The mid-cap company has equity capital of Rs 65.84 crore. Face value per share is Rs 10.

Jubilant FoodWorks said that the board of directors of the company at a meeting held on 19 September accepted resignation of Ajay Kaul as the chief executive officer (CEO) cum whole time director of the company. He has decided to step down as the CEO cum whole time director of the company to evaluate and pursue opportunities outside the Jubilant Bhartia group. Ajay Kaul will continue in his current role till 31 March 2017. The company has also initiated the process of identifying his successor.

Jubilant FoodWorks net profit declined 31.1% to Rs 19 crore on 6.7% growth in net sales to Rs 608.76 crore in Q1 June 2016 over Q1 June 2015.

Jubilant FoodWorks and its subsidiary operates Dominos Pizza brand with the exclusive rights for India, Nepal, Bangladesh and Sri Lanka.

Powered by Capital Market - Live News

Volumes jump at Castrol India counter
Sep 20,2016

Castrol India clocked volume of 5.7 crore shares by 13:25 IST on BSE, a 346.51-times surge over two-week average daily volume of 1.65 lakh shares. The stock was up 8.75% at Rs 459.40.

Apcotex Industries notched up volume of 4.8 lakh shares, a 156.64-fold surge over two-week average daily volume of 3,000 shares. The stock rose 4.83% at Rs 397.

Jyothy Laboratories saw volume of 4.98 lakh shares, a 24.27-fold surge over two-week average daily volume of 21,000 shares. The stock rose 2.97% at Rs 345.05.

MCX (India) clocked volume of 2.85 lakh shares, a 10.59-fold surge over two-week average daily volume of 27,000 shares. The stock rose 3.68% at Rs 1,025.

Virinchi saw volume of 8.5 lakh shares, a 6.66-fold rise over two-week average daily volume of 1.28 lakh shares. The stock was locked at 10% upper circuit at Rs 84.70.

Powered by Capital Market - Live News

NBCC (India) gains after being nominated as LMA
Sep 20,2016

The announcement was made after market hours yesterday, 19 September 2016.

Meanwhile, the S&P BSE Sensex was down 111.99 points or 0.39% at 28,522.51

On BSE, so far 81,000 shares were traded in the counter as against average daily volume of 2.43 lakh shares in the past one quarter. The stock hit a high of Rs 258.95 and a low of Rs 252.05 so far during the day. The stock had hit a 52-week high of Rs 267 on 13 July 2016. The stock had hit a 52-week low of Rs 162 on 12 February 2016. The stock had outperformed the market over the past 30 days till 19 September 2016, rising 4.14% compared with Sensexs 1.99% rise. The scrip also outperformed the market in past one quarter, gaining 35.93% as against Sensexs 6.79% rise.

The large-cap company has equity capital of Rs 120 crore. Face value per share is Rs 2.

NBCC (India) announced that it has been nominated as the Land Management Agency (LMA) for disposal of land assets of the sick central public sector enterprises (CPSEs). NBCC (India) as LMA, will manage, maintain and protect the land assets of sick CPSEs and shall be paid fee for the same till it is disposed off.

NBCC (India) in consultation with the concerned CPSE will prepare development plan of each land parcel after examining prevailing development control norms. Further, the company will also invite expression of interest (EOI) and will offer for purchase of land at the prevailing circle rate/ acquisition cost from all government entities in order of priority. NBCC (India) will be paid 0.5% of the value realized from disposal of land, subject to maximum of Rs 1 crore in each case. The governments measure for utilisation of the idle land of different sick CPSEs in time bound manner, will definetly boost the countrys economy and give enormous business opportunities to the company, NBCC (India) said. It may be recalled that the Government of India had on 7 September 2016 issued a guidelines for closure of sick/ loss making CPSEs including disposal of their movable and immovable assets.

NBCC (India)s consolidated net profit rose 16.4% to Rs 47.10 crore on 15.1% rise in net sales to Rs 1254.31 crore in Q1 June 2016 over Q1 June 2015.

NBCC (India) is a blue-chip Government of India (GoI) Navratna Enterprise under the Ministry of Urban Development, in construction sector. The GoI held 90% stake in the firm (as per shareholding pattern as on 30 June 2016).

Powered by Capital Market - Live News

Bharat Rasayan hits record high after robust Q1 result
Sep 20,2016

The announcement was made after market hours yesterday, 19 September 2016.

Meanwhile, the S&P BSE Sensex was down 116.83 points or 0.41% at 28,517.67

On BSE, so far 6,855 shares were traded in the counter as against average daily volume of 599 shares in the past one quarter. The stock hit a high of Rs 1,730 in intraday trade so far, which is record high for the counter. The stock hit a low of Rs 1,598 so far during the day. The stock had hit a 52-week low of Rs 800 on 9 November 2015.

The small-cap company has equity capital of Rs 4.25 crore. Face value per share is Rs 10.

Bharat Rasayan serves a wide range of industries including but not limited to pharmaceuticals, bulk drugs, R&D, petrochemicals, flavors & fragrances and specialty chemicals. The company provides custom manufacturing/contract manufacturing of diverse compounds to meet the unique needs of every client. In addition, it offers a number of grignard reagents, pharma / drug intermediates and solvents on a regular basis.

Powered by Capital Market - Live News

Cadila Healthcare gains after partnering with Takeda
Sep 20,2016

The announcement was made during market hours today, 20 September 2016.

Meanwhile, the BSE Sensex was down 95.27 points, or 0.33%, to 28,539.23.

On BSE, so far 92,989 shares were traded in the counter, compared with average daily volume of 1.08 lakh shares in the past one quarter. The stock hit a high of Rs 410.90 and a low of Rs 372.30 so far during the day. The stock hit a record high of Rs 454.40 on 23 October 2015. The stock hit a 52-week low of Rs 295.50 on 18 January 2016. The stock had outperformed the market over the past one month till 19 September 2016, gaining 3.92% compared with Sensexs 1.99% rise. The scrip had also outperformed the market in past one quarter, gaining 23.54% as against Sensexs 7.54% rise.

The large-cap company has equity capital of Rs 102.37 crore. Face value per share is Re 1.

Cadila Healthcare and Takeda Pharmaceutical Company (Takeda) announced a partnership to tackle chikungunya, an emerging infectious disease. The chikungunya virus is most often spread to people by Aedes aegypti and Aedes albopictus mosquitoes, the same vectors that spread dengue and zika. The broad-based agreement includes early stage development to the final commercialisation of the vaccine. There is currently no vaccine to prevent or medicine to treat chikungunya virus infection. Terms of the agreement are not disclosed, but it is expected that this partnership will boost access to medicines in the future through this novel partnership.

Chikungunya has been identified in over 60 countries in Asia, Africa, Europe and the Americas. After the bite of an infected mosquito, onset of illness occurs usually between 4 and 8 days but can range from 2 to 12 days. In some people, the joint pain may persist for months. People at risk for severe indications include newborns infected around the time of birth, older adults (≥65 years), and people with medical conditions such as high blood pressure, diabetes, or heart disease.

Since 2005, India, Indonesia, Maldives, Myanmar and Thailand have reported over 19 lakh cases and almost 13 lakh suspected cases of Chikungunya being recorded in the Caribbean islands, Latin American countries, and the United States of America till 2015.

On a consolidated basis, Cadila Healthcares net profit fell 22.6% to Rs 356.20 crore on 2.2% decline in net sales to Rs 2216.40 crore in Q1 June 2016 over Q1 June 2015.

Cadila Healthcare is a global pharmaceutical company that discovers, manufactures and markets a broad range of healthcare therapies.

Powered by Capital Market - Live News

Fiem Industries gains on plans to raise funds
Sep 20,2016

The announcement was made after market hours yesterday, 19 September 2016.

Meanwhile, the S&P BSE Sensex was down 99.45 points or 0.35% at 28,535.58.

On BSE, so far 4,700 shares were traded in the counter as against average daily volume of 8,078 shares in the past one quarter. The stock hit a high of Rs 1,075 and a low of Rs 1,048 so far during the day. The stock had hit a record high of Rs 1,140 on 9 September 2016. The stock had hit a 52-week low of Rs 500 on 18 September 2015. The stock had underperformed the market over the past one month till 19 September 2016, falling 0.42% compared with Sensexs 1.99% rise. The scrip had, however, outperformed the market in past one quarter, gaining 23.29% as against Sensexs 7.54% rise.

The small-cap company has equity capital of Rs 11.96 crore. Face value per share is Rs 10.

Fiem Industries said that the fund raising committee of the board of directors at a meeting held yesterday, 19 September 2016 approved the allotment of 11.97 lakh equity shares of face value of 10 each to qualified institutional buyers at the issue price of Rs 1002 per share, aggregating to Rs 119.99 crore.

Fiem Industries net profit rose 20.4% to Rs 11.46 crore on 19.6% growth in net sales to Rs 241.53 crore in Q1 June 2016 over Q1 June 2015.

Fiem Industries is one of the leading manufacturers of automotive lighting & signaling equipment and rear view mirror.

Powered by Capital Market - Live News

RInfra rises as board approves including new activities
Sep 20,2016

The announcement was made after market hours yesterday, 19 September 2016.

Meanwhile, the S&P BSE Sensex was down 113.15 points, or 0.4%, to 28,521.35

On BSE, so far 1.85 lakh shares were traded in the counter, compared with average daily volume of 4.27 lakh shares in the past one quarter. The stock hit a high of Rs 605.80 and a low of Rs 597.05 so far during the day. The stock hit a 52-week high of Rs 635.35 on 9 September 2016. The stock hit a 52-week low of Rs 322 on 23 September 2015. The stock had underperformed the market over the past 30 days till 19 September 2016, rising 0.21% compared with Sensexs 1.99% rise. The scrip, however, outperformed the market in past one quarter, rising 9.58% as against Sensexs 6.79% rise.

The large-cap company has equity capital of Rs 262.99 crore. Face value per share is Rs 10.

Reliance Infrastructure (RInfra) announced that the board of directors of the company approved to amend the Object Clause of the Memorandum of Association of the company to include new activities relating to setting up any Trust, Funds including Venture Capital Funds, Infrastructure Investment Trust and Real Estate Investment Trust and other Alternative Investment Funds and defence business.

Reliance Infrastructures consolidated net profit rose 7.22% to Rs 438.80 crore on 2.58% rise in net sales to Rs 7032.83 crore in Q1 June 2016 over Q1 June 2015.

RInfra is one of the largest infrastructure companies, developing projects through various special purpose vehicles (SPVs) in several high growth sectors such as power, roads and metro rail in the infrastructure space and the defence sector.

Powered by Capital Market - Live News

Canara Bank gains on capital raising plans
Sep 20,2016

The announcement was made after market hours yesterday, 19 September 2016.

Meanwhile, the S&P BSE Sensex was down 84.67 points or 0.3% at 28,549.83.

On BSE, so far 1.22 lakh shares were traded in the counter as against average daily volume of 4.55 lakh shares in the past one quarter. The stock hit a high of Rs 308 and a low of Rs 303.25 so far during the day. The stock had hit a 52-week high of Rs 316.75 on 9 September 2016. The stock had hit a 52-week low of Rs 156.20 on 29 February 2016. The stock had outperformed the market over the past one month till 19 September 2016, rising 13.69% compared with Sensexs 1.99% rise. The scrip had also outperformed the market in past one quarter, surging 49.19% as against Sensexs 7.54% rise.

The large-cap PSU bank has equity capital of Rs 542.99 crore. Face value per share is Rs 10.

Canara Bank said that the board of directors of the bank at a meeting scheduled on 23 September 2016 will note the consent of the Government of India on infusion of capital and rights issue. The board will also consider raising of capital by way of a rights issue and strengthening of capital to risk weighted assets ratio (CRAR) of the bank in that meet.

Canara Banks net profit fell 52.2% to Rs 228.95 crore on 3.8% decline in total income to Rs 11786.35 crore in Q1 June 2016 over Q1 June 2015.

The Government of India held 66.3% stake in Canara Bank as per the shareholding pattern as on 30 June 2016.

Powered by Capital Market - Live News

Karur Vysya Bank gains as board approves stock-split plan
Sep 20,2016

The announcement was made after market hours yesterday, 19 September 2016.

Meanwhile, the BSE Sensex was down 72.50 points, or 0.25%, to 28,562

On BSE, so far 22,000 shares were traded in the counter, compared with average daily volume of 24,500 shares in the past one quarter. The stock hit a high of Rs 485.50 and a low of Rs 480.10 so far during the day. The stock hit a 52-week high of Rs 541.40 on 11 July 2016. The stock hit a 52-week low of Rs 393.90 on 29 February 2016. The stock had underperformed the market over the past 30 days till 19 September 2016, falling 5.24% compared with Sensexs 1.99% rise. The scrip had also underperformed the market in past one quarter, dropping 2.28% as against Sensexs 6.79% rise.

The mid-cap private sector bank has an equity capital of Rs 121.86 crore. Face value per share is Rs 10.

Karur Vysya Banks net profit rose 8.7% to Rs 146.35 crore on 1.9% rise in total income to Rs 1547.31 crore in Q1 June 2016 over Q1 June 2015.

Karur Vysya Bank has 667 branches and 1655 ATMs as on 31 March 2016.

Powered by Capital Market - Live News

Lloyd Electric & Engg gains after winning contract
Sep 20,2016

The announcement was made after market hours yesterday, 19 September 2016.

Meanwhile, the BSE Sensex was down 62.92 points, or 0.22%, to 28,571.58.

More than usual volumes were witnessed on the counter. On BSE, so far 1.15 lakh shares were traded in the counter, compared with an average volume of 59,860 shares in the past one quarter. The stock hit a high of Rs 282.70 and a low of Rs 276.20 so far during the day. The stock hit a record high of Rs 328.80 on 21 December 2015. The stock hit a 52-week low of Rs 175.90 on 29 February 2016. The stock had outperformed the market over the past one month till 19 September 2016, rising 15.58% compared with Sensexs 1.99% rise. The scrip had also outperformed the market in past one quarter, rising 15.17% as against Sensexs 7.54% rise.

The small-cap company has an equity capital of Rs 40.33 crore. Face value per share is Rs 10.

Lloyd Electric & Engineering has been awarded a contract worth $18 million by GE Transportation to supply custom designed air conditioning units for the Indian Railways Marhowra Locomotive project. The contract is to design, manufacture, test and supply air conditioning units to be manufactured in Lloyds factory in Bhiwadi, Rajasthan over a period of 11 years. Design of the equipment will be a collaborative effort within the Lloyd group of companies and led by Lloyds recently acquired subsidiary Noske-Kaeser Rail & Vehicle New Zealand, based in Palmerston North, New Zealand.

The air conditioning units to be manufactured by Lloyd are to provide driver comfort for 1,000 diesel locomotives to be manufactured in a new plant being built by GE Transportation in Marhowra, Bihar. This project advances the Make in India initiative.

Net profit of Lloyd Electric & Engineering rose 28.9% to Rs 43.90 crore on 25.8% rise in net sales to Rs 893.63 crore in Q1 June 2016 over Q1 June 2015.

Lloyd Electric and Engineering is one of the largest manufacturers of air conditioner coils in India. It also manufactures air conditioners for the Indian railways, metro rail and buses.

Powered by Capital Market - Live News

Mangalam Cement gains after starting production at new grinding unit
Sep 20,2016

The announcement was made after market hours yesterday, 19 September 2016.

Meanwhile, the S&P BSE Sensex was down 66.59 points or 0.23% at 28,567.91.

On BSE, so far 18,332 shares were traded in the counter as against average daily volume of 19,711 shares in the past two weeks. The stock hit a high of Rs 350 and a low of Rs 345 so far during the day. The stock had hit a record high of Rs 375.15 on 23 August 2016. The stock had hit a 52-week low of Rs 151.10 on 25 February 2016. The stock had underperformed the market over the past one month till 19 September 2016, falling 5.62% compared with Sensexs 1.99% rise. The scrip had, however, outperformed the market in past one quarter, rising 16.45% as against Sensexs 7.54% rise.

The small-cap company has equity capital of Rs 26.69 crore. Face value per share is Rs 10.

Mangalam Cement said that it has commenced commercial production at the new cement grinding unit with a capacity of 0.75 million ton per annum (MTPA) at Aligarh, Uttar Pradesh. The overall capacity is now enhanced from 3.25 MTPA to 4 MTPA.

Mangalam Cement reported net profit of Rs 22.59 crore in the quarter ended 30 June 2016 compared with net loss of Rs 18.91 crore in the quarter ended 30 June 2015. Sales rose 6% to Rs 224.13 crore in the quarter ended 30 June 2016 over the quarter ended 30 June 2015.

Mangalam Cement is a cement manufacturing company.

Powered by Capital Market - Live News

KPR Mill hits record high as board to consider stock-split plan
Sep 20,2016

The announcement was made after market hours yesterday, 19 September 2016.

Meanwhile, the S&P BSE Sensex was down 100.29 points or 0.35% at 28,553.99

On BSE, so far 314 shares were traded in the counter as against average daily volume of 6,936 shares in the past one quarter. The stock hit a high of Rs 1,241.90 in intraday trade so far, which is record high for the counter. The stock hit a low of Rs 1,190.05 so far during the day. The stock had hit a 52-week low of Rs 620 on 17 February 2016.

The mid-cap company has equity capital of Rs 37.68 crore. Face value per share is Rs 10.

KPR Mills net profit rose 24.52% to Rs 62.87 crore on 5.87% growth in net sales to Rs 638.81 crore in Q1 June 2016 over Q1 June 2015.

KPR Mill is engaged in manufacture of readymade knitted apparel, cotton knitted fabric and yarn in India.

Powered by Capital Market - Live News

Dr Reddys Lab inches up after launching Paricalcitol injection
Sep 20,2016

The announcement was made after market hours yesterday, 19 September 2016.

Meanwhile, the S&P BSE Sensex was down 50.36 points or 0.18% at 28,584.14

On BSE, so far 1,437 shares were traded in the counter as against average daily volume of 39,235 shares in the past one quarter. The stock hit a high of Rs 3,190 and a low of Rs 3,165 so far during the day. The stock had hit a a record high of Rs 4,382.95 on 20 October 2015. The stock had hit a 52-week low of Rs 2,750 on 21 January 2016.

The large-cap company has equity capital of Rs 85.39 crore. Face value per share is Rs 5.

Dr Reddys Laboratories said it has launched Paricalcitol injection, USP, a therapeutic equivalent generic version of Zemplar (Paricalcitol) injection in the United States market approved by the US Food & Drug Administration (USFDA). The Zemplar brand and generic had US sales of approximately $22.5 million MAT for the most recent twelve months ending in July 2016 according to IMS Health. Dr. Reddys Paricalcitol Injection is available in 2 mcg, 5 mcg, and 10 mcg, and is the first ANDA product launched in the US market.

Dr Reddys Laboratories consolidated net profit fell 76.3% to Rs 153.50 crore on 14.1% decline in total income to Rs 3289.50 crore in Q1 June 2016 over Q1 June 2015.

Dr Reddys Laboratories is an integrated global pharmaceutical company. It offers a portfolio of products and services including active pharmaceutical ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Powered by Capital Market - Live News

Glenmark Pharma gains as subsidiary announces strategic development and global licensing agreement
Sep 19,2016

The announcement was made during market hours today, 19 September 2016.

Meanwhile, the S&P BSE Sensex was up 34.53 points, or 0.12%, to 28,633.56

On BSE, so far 74,000 shares were traded in the counter, compared with average daily volume of 67,669 shares in the past one quarter. The stock hit a high of Rs 929 and a low of Rs 906.80 so far during the day. The stock hit a 52-week high of Rs 1,074.90 on 6 October 2015. The stock hit a 52-week low of Rs 671.50 on 12 February 2016. The stock had outperformed the market over the past 30 days till 16 September 2016, rising 4.51% compared with 1.69% rise in the Sensex. The scrip also outperformed the market in past one quarter, rising 20.61% as against Sensexs 7.41% rise.

The large-cap company has equity capital of Rs 28.22 crore. Face value per share is Re 1.

Glenmark Pharmaceuticals said that its US-based subsidiary, Glenmark Pharmaceuticals Inc., USA, (Glenmark) today, 19 September 2016 announced that it has entered into a strategic development, license and commercialization agreement with Particle Sciences, Inc. to develop and market a generic version of Celgenes ABRAXANE product - paclitaxel protein (albumin)-bound particles for injectable suspension. As per the terms of the agreement, Glenmark has obtained global exclusive marketing and distribution rights of the product upon commercialization. Particle Sciences will develop this product exclusively for Glenmark, and shall receive certain milestone payments during various stages of the products development from Glenmark, including royalties on sales. Development of the product has been initiated for the USA market and Glenmark intends to file the Abbreviated New Drug Application (ANDA) in the year ending 31 March 2019 (FY19). The product will be subsequently filed in other key markets across the globe, Glenmark said.

ABRAXANE marketed globally by Celgene has reported sales of $967 million world-wide and $654 million in the USA in the calendar year 2015. As per IMS MAT December 2015, ABRAXANE has registered sales of $990 million world-wide and $669 million in the USA.

Glenmark Pharmaceuticals consolidated net profit rose 23.96% to Rs 226.78 crore on 22.13% increase in total income to Rs 2018.97 crore in Q1 June 2016 over Q1 June 2015.

Glenmark Pharmaceuticals (GPL) is an integrated pharmaceutical organization. GPL is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).

Powered by Capital Market - Live News